
Precision Medicine in Oncology
Latest Content
Latest Videos

More News

Researchers have found that the number of variants a patient had in their plasma had prognosis implications, with circulating cell-free DNA mutational load having a significant association with overall survival.

Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on the success of tyrosine kinase inhibitors (TKIs) in the treatment of blood cancers and efficacy implications of these therapies for solid tumor cancers.

Based on difference-in-difference (DID) analysis, genomics-informed treatment increased time to treatment discontinuation by an estimated 3 months and increased costs by an estimated C$90,000—equivalent to approximately US$72,000—compared with standard care treatment.

In part 7 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed telehealth and the role of remote care.

In part 6 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed examples of game-changing therapy in cancer care.

In part 5 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed why AccessHope offers an option to payers and oncologists.

In part 4 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how the therapeutic pipeline has changed.

In part 3 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed the payer perspective in the rise of genomics.

In part 2 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how genomics have changed the cancer care landscape.

In the latest Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed designing genomic testing in cancer care.

Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on the efficacy data of mobocertinib in patients with EGFR exon 20 mutations within metastatic non–small cell lung cancer (NSCLC) and its potential significance for these patient populations.

Years of research has shown that in cancers like melanoma, liquid biopsy enables the detection of biomarkers, such as circulating tumor cells, circulating tumor DNA, and exomes.

Based on the prognostic value observed in the study, the researchers suggest that evaluating circulating tumor DNA (ctDNA) status as early as within a week of surgery could aid in risk stratification of patients and decision-making for postoperative management.

Minimal residual disease, overall response rate, complete response rate, and stringent complete response may be useful as surrogate end points to estimate progression-free survival (PFS) benefit for patients with newly diagnosed multiple myeloma.

Christopher Arendt, PhD, head of the Oncology Therapeutic Area Unit at Takeda, discusses pathogenesis and characteristics of EGFR exon 20 mutations in metastatic non–small cell lung cancer (NSCLC).

New research presented at the 2021 American Society of Clinical Oncology Annual Meeting is painting a clearer picture of what drives differences in mortality and outcomes for patients with prostate cancer. Black men with prostate cancer have higher incidence of both.

Favorable genetic characteristics may be able to predict which patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who were treated with venetoclax-rituximab will attain undetectable minimal residual disease (MRD).

Camille Hertzka, vice president and head of Oncology, US Medical, AstraZeneca, speaks about the real-world data collection of durvalumab to assess applicability in patients not involved in the PACIFIC trial, and the importance of diversity and inclusion in clinical trials moving forward.

The study explores data on liquid biopsy approaches outside of circulating tumor DNA—a commonly used approach for liquid biopsy—and includes novel methods like non-coding RNA.

Antoine Italiano, MD, PhD, head of Early Phase Trials and Sarcoma Units at Institut Bergonié, Bordeaux, France, addresses findings of an extended follow-up of larotrectinib in patients with TRK fusion cancer that indicated prolonged progression-free survival in those undergoing the NTRK inhibitor.

ASCO officials characterized the results as practice changing and said they highlighted the need for genetic testing in patients who receive a diagnosis of high-risk breast cancer.

Researchers underscored the importance of addressing these barriers, as artificial intelligence may offer improvements in clinical decision making, broaden access to care, and improve clinical efficiency.

Recent coverage from Targeted Oncology® highlights how combination therapies are impacting the treatment spectrum for chronic lymphocytic leukemia (CLL).

Researchers say increase in immunotherapy was significant over the study period between 2016 and 2018.

Stakeholders identify the value elements of comprehensive genomic profiling (CGP) they find most important, as well as options for innovative contracts.












